Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30525611 | 1.00 | TSHR (0.46) | TSHRCYP3A4CREBBPKDM4EASPH | |
| SCHEMBL29698284 | 0.84 | GABRA1 (0.49) | KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22978618 | 0.84 | GABRA1 (0.49) | KDM4ECYP1A2CYP2C9CYP2C19 | |
| SCHEMBL29743774 | 0.83 | KDM4E (0.41) | KDM4EASPHKDM8PTGS1HTT | |
| SCHEMBL24510117 | 0.83 | KDM4E (0.41) | KDM4EASPHKDM8PTGS1HTT | |
| SCHEMBL24510124 | 0.81 | PDE4A (0.40) | KDM4EASPHKDM8 | |
| SCHEMBL22980867 | 0.80 | CYP3A4 (0.46) | TSHRCYP3A4CREBBPHTT | |
| SCHEMBL24510025 | 0.79 | EPHX2 (0.39) | KDM4EASPHKDM8 | |
| SCHEMBL24509364 | 0.79 | PDE4A (0.44) | KDM4EASPHKDM8ALK | |
| SCHEMBL22978631 | 0.76 | CYP3A4 (0.42) | TSHRCYP3A4HSD17B10CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | ETERN BIOPHARMA (SHANGHAI) CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| EP-4010334-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | Novartis AG (CH) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028806-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021028806-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
| WO-2021026672-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101535-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | WDR5, WDR1, WDR77 | TSHR 4810/4885CYP3A4 2772/4885CREBBP 975/4885 |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | TSHR 4836/4885CYP3A4 4769/4885CREBBP 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.